Formoterol hydrofluoroalkane inhalation - Chiesi

Drug Profile

Formoterol hydrofluoroalkane inhalation - Chiesi

Alternative Names: Atimos; eformoterol; Eformoterol HFA inhalation - Chiesi; Forair; formoterol fumarate; Formoterol HFA 134a; Formoterol HFA inhalation - Chiesi; Formoterol HFA Modulite; Formoterol Modulite

Latest Information Update: 29 Mar 2012

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2011 Takeda acquires Nycomed
  • 26 Jun 2008 Formoterol Modulite® licensed to Nycomed Canada in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top